Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Prostate Cancer:

Prevention of Prostate Cancer Morbidity and Mortality: Primary Prevention and Early Detection. Barry MJ et al. Med Clin North Am. (2017)

Prostate cancer between prognosis and adequate/proper therapy. Grozescu T et al. J Med Life. (2017)

Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography. Rebbeck TR et al. Semin Radiat Oncol. (2017)

Search results

Items: 1 to 20 of 168285

1.

Prostate Cancer Screening (PDQ®): Health Professional Version.

PDQ Screening and Prevention Editorial Board.

PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-.
2019 Oct 18.

2.

Clinical Utility of Mutant Antibody-Based Assays for Determination of Internally Cleaved and Intact Forms of Free Prostate-Specific Antigen.

Khan MFL, Soikkeli M, Routila E, Krannila S, Terävä J, Taimen P, Boström PJ, Pettersson K.

J Appl Lab Med. 2019 May;3(6):1014-1021. doi: 10.1373/jalm.2018.027797. Epub 2019 Feb 1.

PMID:
31639692
3.

Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI.

Tangen CM, Schenk J, Till C, Goodman PJ, Barrington W, Lucia MS, Thompson IM.

Cancer Epidemiol. 2019 Oct 19;63:101619. doi: 10.1016/j.canep.2019.101619. [Epub ahead of print]

PMID:
31639607
4.

Unusual trifecta of infections, aspiration, and metastatic prostatic adenocarcinoma in a bronchoalveolar lavage specimen.

Wang BG, Mani H, Wang ZQ, Nayer Z, Khan J.

Diagn Cytopathol. 2019 Oct 22. doi: 10.1002/dc.24327. [Epub ahead of print]

PMID:
31639284
5.

Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts.

Lange JM, Laviana AA, Penson DF, Lin DW, Bill-Axelson A, Carlsson SV, Newcomb LF, Trock BJ, Carter HB, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Etzioni RB.

Cancer. 2019 Oct 22. doi: 10.1002/cncr.32557. [Epub ahead of print]

PMID:
31639200
6.

PIAS1 is not suitable as a urothelial carcinoma biomarker protein and pharmacological target.

Erb HHH, Ebert M, Kuhn R, Donix L, Haferkamp A, Seed RI, Jüngel E.

PLoS One. 2019 Oct 22;14(10):e0224085. doi: 10.1371/journal.pone.0224085. eCollection 2019.

7.

Correction to: MIIP inhibits the growth of prostate cancer via interaction with PP1α and negative modulation of AKT signaling.

Yan G, Ru Y, Yan F, Xiong X, Hu W, Pan T, Sun J, Zhang C, Wang Q, Li X.

Cell Commun Signal. 2019 Oct 21;17(1):130. doi: 10.1186/s12964-019-0441-4.

8.

TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.

Semaan L, Mander N, Cher ML, Chinni SR.

BMC Cancer. 2019 Oct 21;19(1):972. doi: 10.1186/s12885-019-6185-0.

9.

Nck adapter proteins promote podosome biogenesis facilitating extracellular matrix degradation and cancer invasion.

Chaki SP, Barhoumi R, Rivera GM.

Cancer Med. 2019 Oct 22. doi: 10.1002/cam4.2640. [Epub ahead of print]

10.

TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).

Hofman MS, Emmett L, Violet J, Y Zhang A, Lawrence NJ, Stockler M, Francis RJ, Iravani A, Williams S, Azad A, Martin A, McJannett M; ANZUP TheraP team, Davis ID.

BJU Int. 2019 Oct 22. doi: 10.1111/bju.14876. [Epub ahead of print]

PMID:
31638341
11.

Reply to Comment on Low-Value Prostate Cancer Screening Among Older Men Within the Veterans Health Administration.

Radomski TR, Gellad WF.

J Am Geriatr Soc. 2019 Oct 22. doi: 10.1111/jgs.16203. [Epub ahead of print] No abstract available.

PMID:
31638269
12.

Comment on Low-Value Prostate Cancer Screening among Older Men within the Veterans Health Administration.

Shah N, Ioffe V.

J Am Geriatr Soc. 2019 Oct 22. doi: 10.1111/jgs.16204. [Epub ahead of print] No abstract available.

PMID:
31638268
13.

Comprehensive analysis of the lncRNA‑associated competing endogenous RNA network in breast cancer.

Wang JJ, Huang YQ, Song W, Li YF, Wang H, Wang WJ, Huang M.

Oncol Rep. 2019 Oct 15. doi: 10.3892/or.2019.7374. [Epub ahead of print]

PMID:
31638237
14.

Assessment of biochemical recurrence of prostate cancer (Review).

Lin X, Kapoor A, Gu Y, Chow MJ, Xu H, Major P, Tang D.

Int J Oncol. 2019 Oct 4. doi: 10.3892/ijo.2019.4893. [Epub ahead of print]

PMID:
31638194
15.

The long non-coding RNA GHSROS facilitates breast cancer cell migration and orthotopic xenograft tumour growth.

Thomas PB, Seim I, Jeffery PL, Gahete MD, Maugham M, Crisp GJ, Stacey A, Shah ET, Walpole C, Whiteside EJ, Nelson CC, Herington AC, Luque RM, Veedu RN, Chopin LK.

Int J Oncol. 2019 Oct 4. doi: 10.3892/ijo.2019.4891. [Epub ahead of print]

PMID:
31638176
16.

Editorial Comment to Impact of alternative antiandrogen therapy for Japanese prostate cancer patients in the era of new hormonal therapy.

Akakura K.

Int J Urol. 2019 Oct 21. doi: 10.1111/iju.14141. [Epub ahead of print] No abstract available.

PMID:
31637770
17.

Cancer mortality predictions for 2019 in Latin America.

Carioli G, Bertuccio P, Malvezzi M, Rodriguez T, Levi F, Boffetta P, La Vecchia C, Negri E.

Int J Cancer. 2019 Oct 21. doi: 10.1002/ijc.32749. [Epub ahead of print]

PMID:
31637709
18.

MRI for clinically suspected prostate cancer-the disparity between private and public sectors.

Yap LC, Lynch TH, Manecksha RP.

Ir J Med Sci. 2019 Oct 22. doi: 10.1007/s11845-019-02103-7. [Epub ahead of print]

PMID:
31637636
19.

The association between clinically determined periodontal disease and prostate-specific antigen concentration in men without prostate cancer: the 2009-2010 National Health and Nutrition Examination Survey.

Huang Y, Michaud DS, Lu J, Carter HB, Platz EA.

Cancer Causes Control. 2019 Oct 21. doi: 10.1007/s10552-019-01238-3. [Epub ahead of print]

PMID:
31637561
20.

Identification of key genes and multiple molecular pathways of metastatic process in prostate cancer.

Guo L, Lin M, Cheng Z, Chen Y, Huang Y, Xu K.

PeerJ. 2019 Oct 17;7:e7899. doi: 10.7717/peerj.7899. eCollection 2019.

Supplemental Content

Loading ...
Support Center